LANTHEUS HOLDINGS INC. news, videos and press releases
For more news please use our advanced search feature.
LANTHEUS HOLDINGS INC. - More news...
LANTHEUS HOLDINGS INC. - More news...
- Targa Resources Set to Join S&P 500; Lantheus Holdings to Join S&P MidCap 400; Payoneer Global to Join S&P SmallCap 600
- GE Healthcare and Lantheus Phase III Clinical Trial Finds [18F]flurpiridaz PET Radiotracer Could Improve Detection of Coronary Artery Disease
- Lantheus Announces the First and Only FDA Cleared AI-Enabled PSMA Digital Application, aPROMISE™, Strengthening Lantheus’ Leadership in Prostate Cancer
- Lantheus Holdings, Inc. Reports Second Quarter 2021 Financial Results
- Lantheus Holdings to Host Second Quarter 2021 Earnings Conference Call and Webcast on July 28, 2021 at 8:00 a.m. Eastern Time
- Lantheus To Present Piflufolastat F 18 Data at the Virtual Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2021 Annual Meeting
- Lantheus Receives U.S. FDA Approval of PYLARIFY® (piflufolastat F 18) Injection, the First and Only Commercially Available PSMA PET Imaging Agent for Prostate Cancer
- Lantheus Holdings Announces Presentation Featuring 18F-DCFPyL PET/CT, its PSMA-Targeted Prostate Cancer Imaging Agent at the 2021 ASCO Annual Meeting
- Lantheus Holdings to Present at the Jefferies Virtual Healthcare Conference
- Lantheus Holdings, Inc. Reports First Quarter 2021 Financial Results
- EXINI Diagnostics AB, a Lantheus Company, Receives CE Mark Clearance for aPROMISE in Europe
- Lantheus Grants Allegheny Health Network Exclusive Rights for the Use of its Microbubbles in Combination with Ultrasound Assisted Gene Therapy for the Development of a Proposed Treatment for Xerostomia
- Lantheus Holdings to Host First Quarter 2021 Earnings Conference Call and Webcast on May 4, 2021 at 8:00 a.m. Eastern Time
- Lantheus Expands R&D Leadership Team with Key New Hires
- Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
- Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
- Lantheus Announces Presentation Featuring AZEDRA® (iobenguane I 131) at ENDO 2021
- Lantheus Announces Publication of PyL™ (18F-DCFPyL) Results from Pivotal Studies
- Lantheus Reports Fourth Quarter and Full Year 2020 Financial Results
- Lantheus Holdings to Present at the 10th Annual SVB Leerink Global Healthcare Conference
- Lantheus Holdings to Host Fourth Quarter and Full Year 2020 Earnings Conference Call and Webcast on February 25, 2020 at 4:30 p.m. Eastern Time
- Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting
- Lantheus Holdings Announces Submission of Drug Master File for NM-01 in the U.S.
- Lantheus Holdings Announces Acceptance and Priority Review of New Drug Application for PyLTM (18F-DCFPyL), a PSMA-Targeted Prostate Cancer PET Imaging Agent
- PyL™ (18F-DCFPyL), Lantheus’ PSMA-Targeted Prostate Cancer Imaging Agent, to be Used in POINT Biopharma’s PSMA-Targeted Radioligand Therapeutic Phase 3 Trial in Patients with Metastatic Castration Resistant Prostate Cancer
- Lantheus Holdings, Inc. Announces Agreement to Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility and Enter into Long-Term Supply Agreement
- Lantheus Holdings to Present at the 2020 Evercore ISI HealthCONx Conference
- Lantheus Holdings, Inc. Announces FDA Approval of DEFINITY® Room Temperature
- Lantheus Holdings Announces FDA Clearance for AI-Enabled Automated Bone Scan Index (aBSI) in Prostate Cancer on GE Healthcare’s Xeleris Platform
- CORRECTION: TIME CHANGE - Lantheus Holdings to Present at November 2020 Investor Conferences
